Pharmaceutical News

RSS

Docetaxel decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy

Johns Hopkins Kimmel Cancer Center clinicians were among those at leading institutions that have completed a three-year international study showing that docetaxel, a drug made from yew tree needles, decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy.

11 Jun 2004

New treatment significantly improves long-term outlook for breast cancer survivors

An updated analysis from an international clinical trial of the drug letrozole was presented on June 8, 2004 at the American Society of Clinical Oncology annual meeting in New Orleans.

11 Jun 2004

Drug commonly used for diabetes might be effective in treating multiple sclerosis

Researchers at the University of Illinois at Chicago are launching a clinical trial to determine whether a drug commonly used for diabetes might be effective in treating multiple sclerosis, an autoimmune disease that affects 350,000 Americans.

10 Jun 2004

America's first two WNV encephalitis cases of 2004 respond to treatment

GenoMed, Inc. has announced that the country's second case of West Nile virus encephalitis has responded promptly to its treatment approach. So far, GenoMed's treatment is showing a 100% response rate among 13 immunocompetent patients. The sooner the treatment is instituted, the more rapid and more complete the response.

10 Jun 2004

Remicade shows improvement in both the arthritis and psoriasis associated with psoriatic arthritis

In this trial, REMICADE provided a 70 percent improvement (as measured by ACR 70) in symptoms of arthritis in nearly one-third of patients, compared with only 2 percent of patients on placebo at 24 weeks.

10 Jun 2004

Drug may benefit patients suffering deep scarring after radiation treatment

Cancer patients who suffer from a progressive, deep scarring of tissue following radiation treatment might benefit from a drug that’s FDA-approved to treat vascular disease, according to a University of Rochester study published in this month’s Journal of Clinical Oncology.

10 Jun 2004

Non-aspirin pain drugs may help men with recurrent prostate cancer

Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.

10 Jun 2004

Significant progress in the enrollment of beneficiaries in the Medicare drug discount card program

America's health insurance plans today reported significant progress in the enrollment of beneficiaries in the Medicare-endorsed prescription drug discount card program.

10 Jun 2004

Advertising restrcitions on some over the counter medicines likely to be lifted

Regulations to remove the current ban on advertising certain over the counter (OTC) medicines to the public were laid in Parliament today

9 Jun 2004

Gemcitabine/paclitaxel combination helps breast cancer patients live longer

Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study

9 Jun 2004

Higher generic drug use in 2003 slowed the rising cost per prescription to a 7.9% increase

Generic drug use increased to a record 48% among Express Scripts' 50 million members during 2003, spurred by the use of several prominent new generics, fluoxetine, omeprazole and lisinopril.

9 Jun 2004

SU11248 proves effective in the treatment of gastrointestinal stromal tumors

A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST).

9 Jun 2004

Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer

Men who take even small amounts of common cholesterol-lowering drugs such as Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer, according to a new study by Oregon Health & Science University Cancer Institute researchers.

9 Jun 2004

Gene mutation found in some women may decrease effectiveness of tamoxifen breast cancer drug

Researchers from the Johns Hopkins Kimmel Cancer Center, Indiana University and the University of Michigan have found that some women have a gene mutation that may decrease the effectiveness of tamoxifen, a commonly used breast cancer drug.

7 Jun 2004

Chemotherapy regimen more effective and more toxic in Japanese patients than in American patients

A chemotherapy regimen commonly used to treat non-small cell lung cancer is both more effective and more toxic in Japanese patients than in American patients, researchers reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

7 Jun 2004

Atrasentan reduces cancer risk by 20 percent in men with advanced hormone-resistant prostate cancer

Recent clinical studies led by Johns Hopkins Kimmel Cancer Center researchers have found that a drug called atrasentan reduces the risk by 20 percent that cancer will progress in men with advanced hormone-resistant prostate cancer.

7 Jun 2004

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

A biological agent — a drug that wraps vitamin A inside bubbles of fat — used without chemotherapy appears to offer as many as one-third of patients with a rare form of leukemia an opportunity for a long-term, disease-free future, say researchers at The University of Texas M. D. Anderson Cancer Center.

7 Jun 2004

Herceptin shows real promise in treatment of HER-2 positive breast disease

According to a study conducted at The University of Texas M. D. Anderson Cancer Center, more than twice as many women with early stage, HER-2 positive breast disease who received Herceptin as part of their pre-surgery chemotherapy had their tumors completely disappear compared to like patients who received only chemotherapy.

7 Jun 2004

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M. D. Anderson Cancer Center, who presented their findings at the annual meeting of the American Society of Clinical Oncology.

7 Jun 2004

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the standard diabetes treatment metformin in patients whose diabetes was not adequately controlled by metformin alone.

7 Jun 2004

Pharmaceutical News

Docetaxel decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy

New treatment significantly improves long-term outlook for breast cancer survivors

Drug commonly used for diabetes might be effective in treating multiple sclerosis

America's first two WNV encephalitis cases of 2004 respond to treatment

Remicade shows improvement in both the arthritis and psoriasis associated with psoriatic arthritis

Drug may benefit patients suffering deep scarring after radiation treatment

Non-aspirin pain drugs may help men with recurrent prostate cancer

Significant progress in the enrollment of beneficiaries in the Medicare drug discount card program

Advertising restrcitions on some over the counter medicines likely to be lifted

Gemcitabine/paclitaxel combination helps breast cancer patients live longer

Higher generic drug use in 2003 slowed the rising cost per prescription to a 7.9% increase

SU11248 proves effective in the treatment of gastrointestinal stromal tumors

Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer

Gene mutation found in some women may decrease effectiveness of tamoxifen breast cancer drug

Chemotherapy regimen more effective and more toxic in Japanese patients than in American patients

Atrasentan reduces cancer risk by 20 percent in men with advanced hormone-resistant prostate cancer

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

Herceptin shows real promise in treatment of HER-2 positive breast disease

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News